"TBSF" Human Immunoglobulin for Intravenous Use

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

normal immunoglobulin, Quantity: 60 g/L

Mevcut itibaren:

CSL Behring Australia Pty Ltd

INN (International Adı):

normal immunoglobulin

Farmasötik formu:

Injection, solution

Kompozisyon:

Excipient Ingredients: maltose

Uygulama yolu:

Intravenous

Paketteki üniteler:

50mL, 200mL

Sınıf:

Medicine Listed (Export Only)

Reçete türü:

(S1) This Schedule is intentionally blank

Terapötik endikasyonlar:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Ürün özeti:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Yetkilendirme durumu:

Listed (Export Only)

Yetkilendirme tarihi:

2006-03-01